Valeant
US Congress Committee pressures Valeant to produce drug pricing documents
March 11, 2016Medical Communications, Sales and Marketing Drug pricing, Michael Pearson, Valeant
Valeant’s tough month continued yesterday, with a US congressional committee pressuring the company to explain why it has not produced …
Valeant ends controversial litigation with R&O Pharmacy
March 10, 2016Litigation, Philidor, Valeant, controversy, r&o pharmacy, scandal
Valeant has announced that, in conjunction with R&O Pharmacy, its has jointly requested that the Court dismiss the litigation between …
Valeant company group chairman and executive vice president resigns
March 3, 2016Medical Communications, Sales and Marketing Valeant, appointed, resignation
In an already troubled week for Valeant Pharmaceuticals, the company has now announced that its group chairman and executive vice …
Clinton steps up attacks on Valeant in latest campaign advert
March 2, 2016Research and Development, Sales and Marketing Hilary Clinton, Valeant
This is not the first time the pharma industry has drawn the ire of the US presidential hopefuls, but Hilary …
Valeant shares slide on SEC investigation announcement
March 1, 2016Manufacturing and Production, Research and Development, Sales and Marketing Philidore, Valeant, regulation
Shares at troubled Valeant plummeted some 20% Monday after the company said it was under investigation by the Securities and …
Valeant likely to restate financial results after Philidore review
February 23, 2016Manufacturing and Production, Medical Communications, Sales and Marketing Howard Schiller, Philidore, Valeant
Valeant says it is likely to restate its financial results for the last two years, in the wake of the …
Big pharma answers tough questions at US drug pricing hearing
February 5, 2016Medical Communications Drug pricing, FDA, Martin Shkreli, Senate, Turing Pharmaceuticals, US, Valeant, congress
Pharmaceutical industry executives came under intense scrutiny at a Congressional hearing in the US as the debate over the spiralling …
Martin Shkreli subpoenaed in US to testify over drug pricing
January 21, 2016Medical Communications, Sales and Marketing Daraprim, Howard Schiller, Martin Shkreli, Valeant, turing
Former pharma chief exec Martin Shkreli has been issued with a subpoena by the US House of representatives, compelling him …
Why 2016 could be a make or break year for Valeant
January 8, 2016Medical Communications, Sales and Marketing Howard Schiller, J. Michael Pearson, Michael Pearson, Valeant
This could prove a make-or-break year for Valeant.The specialist drug company begins 2016 with a reputation damaged by allegations of …
Valeant names interim CEO in Pearson’s absence
January 6, 2016Medical Communications, Sales and Marketing Valeant
Valeant has named company director Howard Schiller as interim chief executive officer to serve while full-time boss Michael Pearson is …
Valeant hires attorney and crisis management firm to handle bad US PR
December 17, 2015Medical Communications, Sales and Marketing Robert Kelner, Valeant, Vianovo. Covington & Burling
Valeant has retained attorney Robert Kelner, a partner at the law firm Covington & Burling, to help the beleaguered pharma …
Top five pharma controversies of 2015 (so far)
November 20, 2015Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing
5. AstraZeneca forced to deny tax avoidance allegations
Former Deputy Attorney General called in to advise Valeant after fraud allegations
November 2, 2015Medical Communications, Sales and Marketing Mark Filip, Philidor, Valeant, fraud
Valeant Pharmaceuticals’ board of directors has appointed former Deputy Attorney General of the United States Mark Filip to advise the …
Valeant drops Philidor after prescription fraud row
October 30, 2015Medical Communications, Sales and Marketing Valeant
Valeant has announced that it is ‘severing all ties with Philidor’, the specialty pharmacy at the heart of recent controversy surrounding …
CEO prepares for day of reckoning over Valeant fraud allegations
October 26, 2015Sales and Marketing J. Michael Pearson, Valeant
Troubled Valeant Pharmaceuticals last week announced strong third quarter revenues, reporting a 36% increase in revenues to $172 million, but …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
